Sunday 18 October 2026
Export EYPT’s income statement to Excel — free account
EyePoint, Inc.
EYPT Healthcare Biotechnology
EyePoint, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $31.4 million, down 27.5% from fiscal 2024. In the quarter to June 2026, revenue fell 90.5%, EPS fell 28.2% and free cash flow was flat, each against the same quarter a year earlier. Insiders bought in the last twelve months.
3.00
0.14
−4.46%
Follow EYPT
| Older periods | Sep '25 | Dec '25 | Mar '26 | Jun '26 | |
|---|---|---|---|---|---|
|
+8 more TTM periods Free account |
(98.23%) | (72.19%) | (102.71%) | (148.70%) | |
Piotroski F-Score |
3 | 3 | 2 | 2 | |
| (74.47%) | (59.29%) | (83.47%) | (115.86%) | ||
ROIC |
0.00% | (563,504.63%) | (2,222.02%) | 0.00% | |
Return on Tangible Assets |
(105.58%) | (77.15%) | (122.60%) | (195.45%) | |
Average Days of Receivables |
9.01 | 7.57 | 55.46 | 11.26 | |
Free Cash Flow per Share |
(3.04) | (3.32) | (3.16) | (3.13) | |
Free Cash Flow |
(213.59) | (243.23) | (271.38) | (271.12) | |
Capital Expenditures |
(2.68) | (3.12) | (3.85) | (3.83) | |
| Other line items | |||||
Cash ROIC |
(52.84%) | (39.73%) | (59.91%) | (78.16%) | |
Accounts Receivable Turnover |
59.51 | 49.87 | 9.52 | 7.84 | |
Accounts Payable Turnover |
0.29 | 0.19 | 0.10 | 0.00 | |
Inventory Turnover |
1.02 | 1.00 | 1.06 | 0.00 | |
Average Days of Payables |
1,466.99 | 1,853.27 | 3,838.31 | 0.00 | |
Days of Inventory on Hand |
307.20 | 320.30 | 255.03 | 0.00 | |
Tax Rate |
0.00 | 0.00 | 0.00 | 0.00 | |
Research and Development Expense of Revenue |
484.76% | 704.60% | 3,081.34% | 9,423.57% | |
Selling, General and Administrative Expense of Revenue |
124.97% | 164.80% | 696.55% | 1,987.48% | |
Share Based Compensation of Revenue |
68.55% | 88.85% | 416.22% | 1,263.02% | |
Operating CF/Net income |
1.03 | 1.04 | 0.99 | 0.87 | |
Depreciation/Fixed assets |
(0.41) | (0.28) | (0.15) | (0.03) | |
Capex/Depreciation |
0.74 | 1.24 | 2.70 | 14.60 | |
Revenue per Share |
0.60 | 0.43 | 0.09 | 0.03 | |
Operating CF per Share |
(3.01) | (3.28) | (3.11) | (3.09) | |
Capex per Share |
(0.04) | (0.04) | (0.04) | (0.04) | |
Capex to Sales |
0.06 | 0.10 | 0.51 | 1.37 |
Columns are period end dates